Alzheon, Inc. recently announced the dosing of the first cohort of human volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of ALZ-507, a novel investigational oral drug candidate for the treatment of Alzheimer’s disease.

Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon, commented: “Dosing the first subject with ALZ-507 marks years of scientific progress at Alzheon as we deepen our understanding of Alzheimer’s disease biology. This well-differentiated next-generation Alzheimer’s drug candidate also functions as an APOE4 corrector, strengthening its anti-oligomer properties. ALZ-507 is a major step forward for Alzheon’s precision medicine platform aimed at the prevention of formation of neurotoxic soluble amyloid oligomers. With Alzheimer’s disease still representing a critical global unmet medical need, we are committed to work toward bringing to patients novel, safe, and accessible therapies that have the potential to slow disease progression.”

ALZ-507 is an orally administered small molecule developed to target upstream amyloid aggregation and inhibit the formation of neurotoxic soluble amyloid oligomers, which are recognized as a key trigger and driver of Alzheimer’s disease pathology. Additionally, ALZ-507 features an APOE4 corrector mechanism of action, potentially augmenting its primary anti-oligomer pharmacological effects. Designed as a next-generation oral treatment for Alzheimer’s disease, ALZ-507 may offer the advantages of once-daily dosing and improved gastrointestinal tolerability. The Phase 1 study, employing an oral capsule formulation, will assess the safety, tolerability, and pharmacokinetics in healthy volunteer participants.

“The initiation of the ALZ-507 Phase 1 study with our novel oral product candidate demonstrates the capability of our development platform and our methodical approach to progressing high-quality, disease-modifying oral therapies with optimized pharmaceutical properties,” stated John Hey, PhD, Chief Scientific Officer at Alzheon. “Building on our experience with upstream inhibition of amyloid aggregation, ALZ-507 further expands our portfolio of oral treatments designed to target the main causes of neurodegeneration. Preclinical studies have shown evidence of a positive safety and pharmacokinetic profile, as well as an enhanced efficacy profile, making ALZ-507 a valuable addition to Alzheon’s portfolio of potential disease-modifying treatments for Alzheimer’s disease.”

The Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetics of both single and multiple ascending doses of ALZ-507. Findings from this investigation are anticipated to guide dose selection and inform formulation strategy for subsequent Phase 2 studies involving patients diagnosed with Alzheimer’s disease (AD), Down syndrome–associated AD, and cerebral amyloid angiopathy (CAA).

Valiltramiprosate/ALZ-801 is an investigational oral agent currently in Phase 3 development as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease.^3-7,9,12 Valiltramiprosate is designed to inhibit the formation of neurotoxic soluble beta amyloid oligomers that contribute to cognitive decline in individuals with AD.^4-8,10,15 Preclinical mechanism-of-action studies have demonstrated that ALZ-801 can completely block the formation of these neurotoxic oligomers at the dosage used in Phase 3 clinical trials.^3,9,12,14 Valiltramiprosate employs an enveloping molecular mechanism of action intended to prevent the aggregation of soluble amyloid oligomers in the human brain, ¹⁴ which are associated with the onset and progression of cognitive impairment in AD patients.^3,4,7,9,10 In recognition of its therapeutic promise, valiltramiprosate received Fast Track designation from the U.S. Food and Drug Administration in 2017 for the treatment of Alzheimer’s disease.

Clinical trial data indicate that valiltramiprosate exhibits strong clinical efficacy at the MCI stage, and a favorable safety profile, with no observed increase in the risk of brain vasogenic edema.^1-10,13,15 The initial Phase 3 program for valiltramiprosate targets Early AD patients who are homozygous for the apolipoprotein ε4 allele (APOE4/4), with plans to expand future research to include AD treatment and prevention in individuals carrying one copy of the APOE4 gene.^3-10

An Efficacy and Safety Study of Valiltramiprosate in APOE4/4 Early Alzheimer’s Disease Subjects (NCT04770220): This trial was designed to evaluate the efficacy, safety, biomarker and imaging effects of 265 mg twice daily oral dose of valiltramiprosate in Early AD subjects with two copies of the apolipoprotein ε4 allele (APOE4/4 homozygotes), who constitute approximately 15% of Alzheimer’s patients. This double-blind, randomized trial compared oral valiltramiprosate to placebo treatment over 78 weeks. The APOLLOE4 trial was supported by a grant from the National Institute on Aging to Alzheon, with Susan Abushakra as the principal investigator.

A long-term extension of the trial, APOLLOE4-LTE, evaluated valiltramiprosate in subjects who complete the core APOLLOE4 study for an additional 104 weeks of treatment for a total of 182 weeks or 3.5 years over the core and LTE study. This LTE study ended in January 2026 (NCT06304883).

Biomarker Effects of Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease (NCT04693520): This trial was designed to evaluate the effects of 265 mg twice daily oral dose of valiltramiprosate on biomarkers of AD pathology in subjects with Early AD, who have either the APOE4/4 or APOE3/4 genotype and constitute 65-70% of Alzheimer’s patients. The primary outcome was the change from baseline in plasma p-tau₁₈₁. The trial also included evaluation of clinical efficacy, safety, tolerability, and pharmacokinetic profile of valiltramiprosate over 104 weeks of treatment. A completed long-term extension of the trial evaluated the same dose of valiltramiprosate for an additional 104 weeks of treatment for a total of 208 weeks.³

Alzheon, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a diverse portfolio of product candidates and diagnostic assays for individuals affected by Alzheimer’s disease and other neurodegenerative disorders. The company is focused on innovating therapeutic solutions that directly target the underlying pathology of neurodegeneration. Its lead Alzheimer’s clinical candidate, valiltramiprosate/ALZ-801, is a first-in-class oral agent currently in Phase 3 clinical development as a potentially disease-modifying treatment for Alzheimer’s disease. Valiltramiprosate is an orally administered small molecule shown in preclinical studies to completely inhibit the formation of neurotoxic soluble amyloid oligomers. Its well-differentiated follow-on candidate, ALZ-507, is a once daily oral therapy designed to inhibit the formation of amyloid oligomers while also correcting the high risk APOE4 gene. Leveraging clinical expertise and a robust technology platform, Alzheon pursues drug discovery and development using a precision medicine approach that incorporates individual genetic and biomarker profiles, aiming to advance therapies with meaningful benefits for patients.